Baker Bros. Advisors LP Akero Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $7.9 Billion
- Q1 2024
A detailed history of Baker Bros. Advisors LP transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 2,713,205 shares of AKRO stock, worth $63.7 Million. This represents 0.87% of its overall portfolio holdings.
Number of Shares
2,713,205
Previous 2,368,378
14.56%
Holding current value
$63.7 Million
Previous $55.3 Million
23.93%
% of portfolio
0.87%
Previous 0.64%
Shares
4 transactions
Others Institutions Holding AKRO
# of Institutions
193Shares Held
74.2MCall Options Held
429KPut Options Held
591K-
Janus Henderson Group PLC London, X06.12MShares$144 Million0.09% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$127 Million2.2% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$123 Million3.09% of portfolio
-
Wellington Management Group LLP Boston, MA5.21MShares$122 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$115 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.09B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...